Unique ID issued by UMIN | UMIN000024320 |
---|---|
Receipt number | R000028011 |
Scientific Title | Prospective Epidemiological Research on Functioning Outcomes related to Major Depressive Disorder in Japan |
Date of disclosure of the study information | 2016/10/06 |
Last modified on | 2018/05/14 11:14:45 |
Prospective Epidemiological Research on Functioning Outcomes related to Major Depressive Disorder in Japan
Prospective Epidemiological Research on Functioning Outcomes related to Major Depressive Disorder in Japan (PERFORM-J)
Prospective Epidemiological Research on Functioning Outcomes related to Major Depressive Disorder in Japan
Prospective Epidemiological Research on Functioning Outcomes related to Major Depressive Disorder in Japan (PERFORM-J)
Japan |
Major depressive disorder(MDD)
Psychosomatic Internal Medicine | Psychiatry |
Others
NO
To assess the longitudinal pattern of cognitive function and depressive symptoms in MDD during episodes and following treatment over an observational period of 6 months.
Others
Assessment of the longitudinal pattern of cognitive function and depressive symptoms in MDD during episodes and following treatment
Changes from baseline in digit symbol substitution test (DSST) and Montgomery-Asberg depression scale (MADRS) after 2 and 6 months of treatment.
The number of patients with cognitive dysfunction using multiple measures (DSST, Item 6 of MADRS and PDQ-D) and depressive symptoms (MADRS) in patients with MDD at baseline, after 2 and 6 months of treatment.
The association between cognitive dysfunction and psychosocial function in patients with MDD at baseline, after 2 and 6 months of treatment.
Comparison of quality of life and resource uses between MDD patients with different levels of cognitive dysfunction at baseline, after 2 and 6 months of treatment.
Observational
18 | years-old | <= |
65 | years-old | >= |
Male and Female
Patients who meet all of the following criteria are included in this study.
1.Outpatients
2.Patients aged between 18 and 65 years at the time of informed consent
3.Patients with a current or new diagnosis of major depressive episode according to Diagnostic and Statistical manual of Mental Disorders-IV (DSM-IV-TR); diagnosis will be confirmed through the MINI International Neuropsychiatric Interview (MINI questionnaire) (Major Depressive Episode module).
4.Patients initiating a new antidepressant monotherapy (tricyclic or tetracyclic antidepressant, SSRI, SNRI, NaSSA) at the baseline visit (whether as first line or switch of antidepressant therapy) as decided by the investigator.
5.Patients who, in the opinion of the investigator, are capable of understanding the content of the clinical research and complying with the research protocol requirements.
6.Patients who can sign and date an informed consent form prior to the conduction of the clinical research procedures.
7.Patients who are capable of reading and understanding questionnaire
Patients who fall into any of the following criteria are excluded from participating in this study.
1.Patients who have a concurrent diagnosis or past history of any of the following conditions:
Schizophrenia or other psychotic disorders
.Bipolar disorders
.Dementia or any other neurodegenerative disease
.Substance dependence, including alcohol and other drugs, excluding mild and moderate nicotine dependence. Severe nicotine dependence will be excluded.
.Any psychiatric disorder due to a general medical condition or substances
2.Patients prescribed with more than 1 antidepressant on the day of the baseline visit (combination of 2 or more antidepressants)
3.Patients prescribed antipsychotic on the day of the baseline visit (augmentation of the antidepressant prescription with an antipsychotic)
4.Patients prescribed mood stabilizers on the day of the baseline visit (augmentation of the antidepressant prescription with a mood stabilizer)
5.Patients having current treatment with electroconvulsive therapy (ECT) or repeated transcranial magnetic stimulation (rTMS)
6.Pregnant women, women breast feeding at the start of the research
7.Patients presenting acute suicidality in the investigator's opinion
8.Patients currently enrolled in an interventional clinical research such as clinical trial
9.Member of the research personnel or their immediate families, or subordinates (or immediate family member of a subordinate) to any of the research personnel.
10.Patient who has previously been enrolled in this research
11.Patients who, in the opinion of the investigator, unlikely to comply with the protocol
500
1st name | |
Middle name | |
Last name | Tomiki Sumiyoshi |
National Center of Neurology and Psychiatry
Department of Clinical Epidemiology
4-1-1 Ogawahigashimachi, Kodaira,Tokyo 187-8551, Japan
042-341-2711
sumiyot@ncnp.go.jp
1st name | |
Middle name | |
Last name | Kotaro Senuki |
Sogo Rinsho Medefi Company Limited.
Business promotion department
9F KDX Shinjuku building 3-2-7,Nishishinjuku,Shinjuku-ku,Tokyo
03-6901-6079
PERFORM-J@sogo-medefi.jp
Takeda Pharmaceutical Company Limited.
Takeda Pharmaceutical Company Limited.
Profit organization
NO
2016 | Year | 10 | Month | 06 | Day |
Unpublished
No longer recruiting
2016 | Year | 08 | Month | 25 | Day |
2016 | Year | 10 | Month | 06 | Day |
2018 | Year | 01 | Month | 10 | Day |
2018 | Year | 04 | Month | 02 | Day |
2018 | Year | 05 | Month | 10 | Day |
The prospective clinical study for Functioning Outcomes related to Major Depressive Disorder.
2016 | Year | 10 | Month | 06 | Day |
2018 | Year | 05 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028011